Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this preclinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. Significance: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC. This article is highlighted in the In This Issue feature, p. 1079
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results were replicated in clinical trials (for example, NCT04538664), eventually leading to the approval of amivantamab by the EMA for the treatment of non-small cell lung cancer.”
From Human disease models in drug development (2023) · cites this paper as [115]
In the citing paper
“the efficacy of amivantamab, a bispecific antibody against EGFR and the mesenchymal–epithelial transition receptor, was preclinically tested in patient-derived cells and organoids that harbour EGFR Exon20ins mutations115.”
From Human disease models in drug development (2023) · cites this paper as [115]
Citations
Cites
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“Nearly 20% of Caucasians and up to 50% of Asians with lung adenocarcinomas harbor mutations in EGFR (3,4).”
BackgroundLong‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“PDO Culture PDOs (YUO-029 and YUO-036) were established as described previously (46).”
MethodGazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · cited 1×
“tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and osimertinib (5,6).”
BackgroundRegulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891 · cited 1×
“It is known that inflammatory cytokines such as IFN-γ and TNFα are secreted from infected monocytes and activated NK cells during ADCC, encouraging antigen presentation and adaptive immune responses (36,37).”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (30) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of p-ERK, induction of p-ERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival potentially through the crosstalk between mut…”
BackgroundYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · cited 1×
“In contrast, the EGFR exon 20 mutations encompass nucleotides that translate into amino acids at position 762-823, and include a C-helix (762–766) followed by a loop (767–775) (7).”
BackgroundNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567 · cited 1×
“The effector cells, mainly natural killer (NK) cells, trigger degranulation and subsequent cytokine production, resulting in the elimination of the target cells (33).”
BackgroundIntra-tumour diversification in colorectal cancer at the single-cell level
Roerink, S. F., Sasaki, N., Lee-Six, H., Young, M. D., Alexandrov, L. B., Behjati, S., Mitchell, T. J., Grossmann, S., Lightfoot, H., Egan, D. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0024-3 · Cited by 551
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · cited 1×
“As EGFR-TKIs have been reported to drive apoptosis in NSCSL cells harboring sensitizing EGFR mutations (24,25), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
BackgroundRobichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468 · cited 12×
“In a single-center phase II trial, poziotinib showed a 43% confirmed RR in heavily pretreated advanced EGFR Exon20ins–mutant NSCLC (21).”
BackgroundMethodInfluentialTargeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370 · cited 1×
“tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and osimertinib (5,6).”
BackgroundNatural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · cited 1×
“thus representing an area of high unmet medical needs (10,11).”
BackgroundWang, R., Jaw, J. J., Stutzman, N. C., Zou, Z., & Sun, P. D. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0611308 · Cited by 301 · cited 1×
“In addition, immunocytokines secreted from NK cells lead to upregulation of ICAM1 on target cells, rendering them more susceptible to target cell cytolysis (41).”
BackgroundCanale, M., Petracci, E., Delmonte, A., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., De Luigi, N., Mariotti, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0966 · Cited by 288 · cited 9×
“© 2020 American Association forcancerdiscovery.aacrjournals.org Downloaded from Amivantamab in NSCLC with EGFR Exon20ins RESEARCH ARTICLE AUGUST 2020 CANCER DISCOVERY | 1199 in TP53 commonly occurred with EGFR mutations in NSCLC.”
BackgroundInfluentialMoores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286 · cited 1×
“L858R and Exon 19 deletions) (16), its activity has not yet been explored in the context of EGFR Exon20ins.”
BackgroundSelf-citationOkada, S., Vaeteewoottacharn, K., & Kariya, R. (2019) · Cells · doi:10.3390/cells8080889 · Cited by 263 · cited 1×
“As demonstrated in many studies, NOG mice have impaired innate immunity and extremely low NK cell activity, whereas BALB/c nude mice have intact innate immunity and active NK cells (45,46).”
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253 · cited 1×
“According to many studies, anti-EGFR mAb induces internalization of EGFR leading to downregulation of its expression on the cell surface (33,34).”
BackgroundNagano, T., Tachihara, M., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 251 · cited 1×
“Mutations in the epidermal growth factor receptor (EGFR) (1,2) gene constitutively activate downstream growth and survival signaling pathways leading to dependency on the EGFR pathway for tumor growth.”
BackgroundWong, S.-F. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.003 · Cited by 249 · cited 1×
“In this study, amivantamab demonstrated more robust ADCC in EGFR Exon20ins mutation models than cetuximab, an EGFR-directed antibody that has not shown robust utility in NSCLC (39, 40).”
BackgroundRiess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240 · cited 1×
“EGFR Exon20 insertion driver mutations (Exon20ins), a distinct and highly heterogeneous subset of NSCLCs, represent 4%-12% of all EGFR mutations (8,9).”
BackgroundNon-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175 · cited 1×
“The human FcγRIIIa, critical for ADCC, binds antibodies with low-level core fucosylation more tightly and consequently mediates more potent and effective ADCC killing of cancer cells (42).”
BackgroundCytokine Secretion Is Distinct from Secretion of Cytotoxic Granules in NK Cells
Reefman, E., Kay, J. G., Wood, S. M., Offenhäuser, C., Brown, D. L., Roy, S., Stanley, A. C., Low, P. C., Manderson, A. P., & Stow, J. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0803954 · Cited by 143 · cited 1×
“It is known that inflammatory cytokines such as IFNγ and TNFα are secreted from infected monocytes and activated NK cells during ADCC, encouraging antigen presentation and adaptive immune responses (34, 35).”
BackgroundShi, P., Oh, Y.-T., Deng, L., Zhang, G., Qian, G., Zhang, S., Ren, H., Wu, G., Legendre, B., Anderson, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1574 · Cited by 142 · cited 1×
“As EGFR TKIs have been reported to drive apoptosis in NSCLC cells harboring sensitizing EGFR mutations (22, 23), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
BackgroundResponse Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131 · cited 4×
“We compared the antitumor activity and safety of poziotinib with those of amivantamab in YU-1163 (S768_D770dup)–bearing BALB/c nude mice and Ba/F3 cells overexpressing D770_N771insSVD-bearing Cancer Research. on November 2, 2021.”
BackgroundInfluentialEGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., & Zhang, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5820-0 · Cited by 129 · cited 1×
“Mutations in the epidermal growth factor receptor (EGFR) (1,2) gene constitutively activate downstream growth and survival signaling pathways leading to dependency on the EGFR pathway for tumor growth.”
BackgroundMolecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K Signaling
Conde, E., Angulo, B., Tang, M., Morente, M. M., Torres‐Lanzas, J., Encuentra, Á. L., López‐Ríos, F., & Sánchez‐Céspedes, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1362 · Cited by 118
NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice
Puchalapalli, M., Zeng, X., Mu, L., Anderson, A., Glickman, L. H., Zhang, M., Sayyad, M. R., Wangensteen, S. M., Clevenger, C. V., & Koblinski, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163521 · Cited by 118
Haura, E. B., Cho, B. C., Lee, J. S., Han, J.-Y., Lee, K. H., Sanborn, R. E., Govindan, R., Cho, E. K., Kim, S.-W., Reckamp, K. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9009 · Cited by 96 · cited 3×
“Antitumor activity of amivantamab in patients with EGFR Exon20ins disease In an ongoing first-in-human study of amivantamab in patients with advanced NSCLC (NCT02609776), promising clinical activity has been observed in patients with EGFR Exon20ins disease (15).”
BackgroundSelf-citationAggarwal, C., Davis, C. W., Mick, R., Thompson, J. C., Ahmed, S., Jeffries, S., Bagley, S. J., Gabriel, P. E., Evans, T. L., Bauml, J. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00107 · Cited by 95 · cited 7×
“As EGFR TKIs have been reported to drive apoptosis in NSCLC cells harboring sensitizing EGFR mutations (22, 23), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
BackgroundInfluentialAlam, S. K., Yadav, V. K., Bajaj, S., Datta, A., Dutta, S. K., Bhattacharyya, M., Bhattacharya, S., Debnath, S., Roy, S., Boardman, L. A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.133 · Cited by 91 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (30) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of p-ERK, induction of p-ERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival potentially through the crosstalk between mut…”
BackgroundSellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 91
Grugan, K. D., Dorn, K., Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Laquerre, S., Moores, S. L., & Chiu, M. L. (2017) · mAbs · doi:10.1080/19420862.2016.1249079 · Cited by 86 · cited 6×
“In contrast to many other therapeutic antibodies used in the clinical setting, amivantamab was designed and engineered with a low fucose backbone, which enhances its binding to FcγRIIIa (19), which is present on NK cells, monocytes and macrophages.”
BackgroundResultInfluentialHeymach, J. V., Negrao, M. V., Robichaux, J. P., Carter, B. W., Patel, A. P., Altan, M., Gibbons, D. L., Fossella, F. V., Simon, G. R., Lam, V. K. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.243 · Cited by 85
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells
Sauer, L., Gitenay, D., Vo, C., & Baron, V. T. (2010) · Oncogene · doi:10.1038/onc.2010.24 · Cited by 82 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (28) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of pERK, induction of pERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival, potentially through the cross-talk between mut…”
BackgroundCha, M. Y., Lee, K., Kim, M., Song, J. Y., Lee, K. H., Park, J., Chae, Y. J., Kim, Y. H., Suh, K. H., Lee, G. S., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26276 · Cited by 79 · cited 1×
“As reported in a previous study (20), poziotinib also potently suppressed proliferation of Ba/F3 cells harboring WT EGFR (IC50 = 0.”
BackgroundZhu, H.-B., Yang, K., Xie, Y.-Q., Lin, Y.-W., Mao, Q.-Q., & Xie, L.-P. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-22 · Cited by 64 · cited 1×
“Indeed, accumulated studies have revealed that the R280T mutation in TP53 plays crucial roles in the proliferation and survival of cancer cells, and knockdown of the mutant TP53 causes G2-phase arrest and apoptosis in bladder cancer cells (26, 27).”
BackgroundEGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 62 · cited 1×
“According to many studies, anti-EGFR mAb induces internalization of EGFR, leading to downregulation of its expression on the cell surface (31, 32).”
BackgroundJarantow, S. W., Bushey, B. S., Pardinas, J. R., Boakye, K., Lacy, E. R., Sanders, R., Sepulveda, M. A., Moores, S. L., & Chiu, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651653 · Cited by 61 · cited 1×
“receptor phosphorylation with amivantamab (39).”
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9007 · Cited by 61
Ramalingam, S. S., Forster, J., Naret, C., Evans, T. L., Sulecki, M., Lu, H., Teegarden, P., Weber, M. R., & Belani, C. P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181653d1b · Cited by 54 · cited 1×
“In this study, amivantamab demonstrated more robust ADCC in EGFR Exon20ins mutation models than cetuximab, an EGFR-directed antibody that has not shown robust utility in NSCLC (39, 40).”
BackgroundCross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Zheng, S., Moores, S., Jarantow, S., Pardinas, J., Chiu, M., Zhou, H., & Wang, W. (2016) · mAbs · doi:10.1080/19420862.2015.1136762 · Cited by 46 · cited 1×
“To this end, amivantamab has been shown to have higher efficacy in decreasing tumor growth in the H1975HGF model compared with the combination of anti-EGFR and anti-MET monovalent antibodies (36).”
BackgroundR280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway
Lin, C., Liang, Y., Zhu, H., Zhang, J., & Zhong, X. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.09.022 · Cited by 22
Frega, S., Lorenzi, M., Fassan, M., Indraccolo, S., Calabrese, F., Favaretto, A., Bonanno, L., Polo, V., Zago, G., Lunardi, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15945 · Cited by 17 · cited 4×
“We compared the antitumor activity and safety of poziotinib with those of amivantamab in YU-1163 (S768_D770dup)–bearing BALB/c nude mice and Ba/F3 cells overexpressing D770_N771insSVD-bearing Cancer Research. on November 2, 2021.”
BackgroundInfluentialSelf-citationCho, B. C., Lee, J.-S., Han, J., Cho, E. K., Haura, E. B., Lee, K. H., Bauml, J. M., Sanborn, R. E., Curtis, M., Attiyeh, E. F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy292.118 · Cited by 15 · cited 2×
“4 NSCLC have demonstrated preliminary clinical activity of amivantamab in patients with diverse EGFR mutations (14,15).”
BackgroundSelf-citationYang, Z., Tchekmedyian, N., Chu, D. T. W., Reddy, G., Bhat, G., & Socinski, M. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps9106 · Cited by 7 · cited 1×
“Recently, poziotinib and TAK-788 have been undergoing clinical evaluation in patients whose tumors carry EGFR Exon20ins mutations (12,13).”
BackgroundPoziotinib Shows Promise for Rare Lung Cancer
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-164 · Cited by 2
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
“Median time from initial diagnosis, months (range) 37 (2-173) 17 (1-130)”
BackgroundSelf-citationThe past, present, and future of antibiotics
Cook, M. A., & Wright, G. D. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7793 · Cited by 652
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Self-citationEmerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
“expression and exhibited immune-directed antitumor activity, translating clinically into robust antitumor responses in two exon 20ins patients.(182) Notably, on May 21, 2021, the FDA granted accelerated approval to JNJ-61186372 (Rybrevant, Janssen Biotech, Inc.”
Background
Metadata
- Authors
- Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C.
- Affiliations
- Yonsei University (KR)
- Jeuk (South Korea) (KR)
- 4Janssen Research and Development, Spring House, Pennsylvania.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1194-1209
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3024670790
- Cited by
- 297
- References
- 47
- Citations by year
- 2026: 32 · 2025: 60 · 2024: 45 · 2023: 52 · 2022: 49 · 2021: 47 · 2020: 11
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Ministry of Science, ICT and Future Planning (NRF-2016R1A2B3016282, 2018R1C1B6008916)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- amivantamab, EGFR-MET bispecific antibody, EGFR exon 20 insertion, non-small cell lung cancer, anticancer activity, EGFR tyrosine kinase inhibitors, immune checkpoint blockade, interferon-gamma, patient-derived organoids, xenograft models, cetuximab, poziotinib, Ba/F3 cells
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Cell Line, Tumor, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.